Overview

Study to Assess the Efficacy and Safety of Meropenem and Pralurbactam in Carbapenem-Resistant Enterobacteriaceae Infections

Status:
RECRUITING

Trial end date:
2027-04-01

Target enrollment:

Participant gender:

Summary

The study will evaluate the efficacy and safety of Meropenem and Pralurbactam versus Best Available Therapy in the treatment of Carbapenem-Resistant Enterobacteriaceae Infections. Infections evaluated in the study will be hospital-acquired bacterial pneumonia (HABP), ventilator-associated bacterial pneumonia (VABP), complicated intra-abdominal infection (cIAI), complicated urinary tract infection (cUTI), and Bloodstream Infection (BSI).

Phase:

PHASE3

Details

Lead Sponsor:

Qilu Pharmaceutical Co., Ltd.

Treatments:

Colistin
Meropenem